Chronic diabetic peripheral neuropathic pain: psychometric properties of pain and physical function outcome measures

Mehta, P; Claydon, LS; Mani, R; Hendrick, P; Cook, C; Baxter, GD

Chronic diabetic peripheral neuropathic pain: psychometric properties of pain and physical function outcome measures

Mehta, P

Claydon, LS Mani, R Hendrick, P Cook, C Baxter, GD

Permalink

Publication Type:: Journal Article
Citation:: Physical Therapy Reviews, 2018, 23 (6), pp. 317 - 329
Issue Date:: 2018-11-02

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted ManuscriptAdobe PDF (1.49 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Mehta, P https://orcid.org/0000-0002-9307-9648	en_US
dc.contributor.author	Claydon, LS	en_US
dc.contributor.author	Mani, R	en_US
dc.contributor.author	Hendrick, P	en_US
dc.contributor.author	Cook, C	en_US
dc.contributor.author	Baxter, GD	en_US
dc.date.available	2020-05-25T19:20:09Z
dc.date.issued	2018-11-02	en_US
dc.identifier.citation	Physical Therapy Reviews, 2018, 23 (6), pp. 317 - 329	en_US
dc.identifier.issn	1083-3196	en_US
dc.identifier.uri	http://hdl.handle.net/10453/134970
dc.description.abstract	© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Background: Diabetic peripheral neuropathy (DPN) not only produces severe pain, tingling, and numbness sensation in the involved limbs, but also limits physical function due to loss of sensation. There are no recommended methods for clinical situations to measure these signs and symptoms. Studies with high methodological quality use the modified Brief Pain Inventory for Diabetic Peripheral Neuropathic pain (mBPI-DPN) scale and the short form Screening of Activity Limitations and Safety Awareness (sSALSA) scale for measuring these symptoms in DPN population. In order to capture a real change in the variables of interest, the psychometric properties of that measure should be within acceptable limits. As these two measures were not assessed for all of the psychometric properties, there was a need for further evaluation. Methods: Data were collected (n = 38 patients) in a longitudinal cohort study. Test–retest reliability (0–4 weeks) and Responsiveness- Minimal Clinically Important Difference (MCID) (0–12 weeks) were calculated between two sessions. Convergent validity was assessed (between mBPI-DPN pain interference and sSALSA scale). Results: Both measures demonstrated acceptable test–retest reliability (mBPI-DPN scale: ICC = 0.61, SEM = 12.92; the sSALSA scale: ICC = 0.81, SEM = 4.88) and convergent validity (Spearman’s correlation coefficient r = 0.62). The computational methods used in different methodologies to calculate MCID for the mBPI-DPN and the sSALSA scale were varied, hence the magnitude of derived MCID scores also varied. Conclusions: Our study have provided evidence to add to the scientific basis surrounding the use of mBPI-DPN and sSALSA scales in DPN population, but standardization of these measures in a larger population is required.	en_US
dc.relation.ispartof	Physical Therapy Reviews	en_US
dc.relation.isbasedon	10.1080/10833196.2018.1517072	en_US
dc.title	Chronic diabetic peripheral neuropathic pain: psychometric properties of pain and physical function outcome measures	en_US
dc.type	Journal Article
utslib.citation.volume	6	en_US
utslib.citation.volume	23	en_US
utslib.for	1103 Clinical Sciences	en_US
utslib.for	1106 Human Movement and Sports Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
utslib.copyright.status	open_access
pubs.issue	6	en_US
pubs.publication-status	Published	en_US
pubs.volume	23	en_US

Abstract:

© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Background: Diabetic peripheral neuropathy (DPN) not only produces severe pain, tingling, and numbness sensation in the involved limbs, but also limits physical function due to loss of sensation. There are no recommended methods for clinical situations to measure these signs and symptoms. Studies with high methodological quality use the modified Brief Pain Inventory for Diabetic Peripheral Neuropathic pain (mBPI-DPN) scale and the short form Screening of Activity Limitations and Safety Awareness (sSALSA) scale for measuring these symptoms in DPN population. In order to capture a real change in the variables of interest, the psychometric properties of that measure should be within acceptable limits. As these two measures were not assessed for all of the psychometric properties, there was a need for further evaluation. Methods: Data were collected (n = 38 patients) in a longitudinal cohort study. Test–retest reliability (0–4 weeks) and Responsiveness- Minimal Clinically Important Difference (MCID) (0–12 weeks) were calculated between two sessions. Convergent validity was assessed (between mBPI-DPN pain interference and sSALSA scale). Results: Both measures demonstrated acceptable test–retest reliability (mBPI-DPN scale: ICC = 0.61, SEM = 12.92; the sSALSA scale: ICC = 0.81, SEM = 4.88) and convergent validity (Spearman’s correlation coefficient r = 0.62). The computational methods used in different methodologies to calculate MCID for the mBPI-DPN and the sSALSA scale were varied, hence the magnitude of derived MCID scores also varied. Conclusions: Our study have provided evidence to add to the scientific basis surrounding the use of mBPI-DPN and sSALSA scales in DPN population, but standardization of these measures in a larger population is required.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/134970